JP2014502955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502955A5 JP2014502955A5 JP2013534894A JP2013534894A JP2014502955A5 JP 2014502955 A5 JP2014502955 A5 JP 2014502955A5 JP 2013534894 A JP2013534894 A JP 2013534894A JP 2013534894 A JP2013534894 A JP 2013534894A JP 2014502955 A5 JP2014502955 A5 JP 2014502955A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102100024152 Cadherin-17 Human genes 0.000 claims 5
- 101710196881 Cadherin-17 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 231100001258 radiotoxin Toxicity 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40509010P | 2010-10-20 | 2010-10-20 | |
| US61/405,090 | 2010-10-20 | ||
| PCT/US2011/001787 WO2012054084A2 (en) | 2010-10-20 | 2011-10-19 | Antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014502955A JP2014502955A (ja) | 2014-02-06 |
| JP2014502955A5 true JP2014502955A5 (OSRAM) | 2014-12-11 |
Family
ID=45975790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534894A Pending JP2014502955A (ja) | 2010-10-20 | 2011-10-19 | 抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130259878A1 (OSRAM) |
| EP (1) | EP2629796A4 (OSRAM) |
| JP (1) | JP2014502955A (OSRAM) |
| KR (1) | KR20130138802A (OSRAM) |
| CN (1) | CN103534268B (OSRAM) |
| AU (1) | AU2011318574B2 (OSRAM) |
| BR (1) | BR112013009551A2 (OSRAM) |
| CA (1) | CA2815041A1 (OSRAM) |
| EA (1) | EA201300470A1 (OSRAM) |
| IL (1) | IL225571A0 (OSRAM) |
| MX (1) | MX2013004476A (OSRAM) |
| NZ (1) | NZ610091A (OSRAM) |
| SG (1) | SG189835A1 (OSRAM) |
| WO (1) | WO2012054084A2 (OSRAM) |
| ZA (1) | ZA201302459B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
| IN2015DN01967A (OSRAM) * | 2012-09-19 | 2015-08-14 | Abbvie Biotherapeutics Inc | |
| CN113817060B (zh) * | 2016-01-09 | 2024-03-08 | 嘉立医疗科技(广州)有限公司 | 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 |
| EP3360898A1 (en) * | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| EP3784990A4 (en) * | 2018-04-26 | 2022-06-22 | The Trustees of the University of Pennsylvania | COMPOSITIONS AND METHODS FOR DETECTING TUMOR-RELATED ANTIBODIES AND ANTIGENS |
| RU2703949C1 (ru) * | 2018-04-27 | 2019-10-22 | Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) | Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены |
| CN112512575B (zh) * | 2018-05-16 | 2024-08-06 | 嘉立医疗科技(广州)有限公司 | 双特异性抗体组合物及其使用方法 |
| US20210116456A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Compositions and methods for diagnosis and treatment of cancer |
| WO2023015169A1 (en) * | 2021-08-02 | 2023-02-09 | Tavotek Biotech (Suzhou) Ltd | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof |
| WO2024100294A1 (en) | 2022-11-11 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Cdh17 car |
| CN120917040A (zh) * | 2023-01-31 | 2025-11-07 | 毕格哈特生物科学公司 | 抗cdh17抗体及其用途 |
| TW202448962A (zh) * | 2023-02-23 | 2024-12-16 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段和使用方法 |
| TW202509083A (zh) * | 2023-05-24 | 2025-03-01 | 大陸商普眾發現醫藥科技（上海）有限公司 | 抗體及其抗體－藥物偶聯物 |
| WO2025061181A1 (en) * | 2023-09-22 | 2025-03-27 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibodies and uses thereof |
| CN120230211A (zh) * | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| WO2025242100A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1996040942A1 (en) * | 1995-06-07 | 1996-12-19 | Cytel Corporation | Humanized antibodies to e-selectin |
| KR101077001B1 (ko) * | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1354896B1 (en) * | 2000-12-28 | 2010-02-10 | Kyowa Hakko Kirin Co., Ltd. | Monoclonal antibody directed against the human bst2 antigen |
| IL149820A0 (en) * | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| JP2006089471A (ja) * | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| RU2404193C2 (ru) * | 2005-03-25 | 2010-11-20 | Дженентек, Инк. | Способ лечения опухоли у субъекта |
| US8535677B2 (en) * | 2006-06-06 | 2013-09-17 | Oxford Biotherapeutics, Ltd. | Antibody drug conjugate treatment of colorectal cancer |
| WO2009116670A1 (ja) * | 2008-03-17 | 2009-09-24 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| EP2399934B1 (en) * | 2009-02-20 | 2017-09-06 | The University of Tokyo | Novel monoclonal antibody, and use thereof |
| JP5748653B2 (ja) * | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法 |
| SG10201401604VA (en) * | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
-
2011
- 2011-10-19 EA EA201300470A patent/EA201300470A1/ru unknown
- 2011-10-19 JP JP2013534894A patent/JP2014502955A/ja active Pending
- 2011-10-19 SG SG2013025242A patent/SG189835A1/en unknown
- 2011-10-19 NZ NZ610091A patent/NZ610091A/en not_active IP Right Cessation
- 2011-10-19 AU AU2011318574A patent/AU2011318574B2/en not_active Ceased
- 2011-10-19 WO PCT/US2011/001787 patent/WO2012054084A2/en not_active Ceased
- 2011-10-19 CA CA2815041A patent/CA2815041A1/en not_active Abandoned
- 2011-10-19 US US13/880,320 patent/US20130259878A1/en not_active Abandoned
- 2011-10-19 CN CN201180050390.8A patent/CN103534268B/zh not_active Expired - Fee Related
- 2011-10-19 EP EP11834758.2A patent/EP2629796A4/en not_active Withdrawn
- 2011-10-19 BR BR112013009551A patent/BR112013009551A2/pt not_active IP Right Cessation
- 2011-10-19 KR KR1020137012771A patent/KR20130138802A/ko not_active Withdrawn
- 2011-10-19 MX MX2013004476A patent/MX2013004476A/es unknown
-
2013
- 2013-04-04 IL IL225571A patent/IL225571A0/en unknown
- 2013-04-05 ZA ZA2013/02459A patent/ZA201302459B/en unknown
-
2014
- 2014-11-20 US US14/549,176 patent/US20150093392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502955A5 (OSRAM) | ||
| JP2011046732A5 (OSRAM) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| JP2015534577A5 (OSRAM) | ||
| JP2016502515A5 (OSRAM) | ||
| JP2018070648A5 (OSRAM) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| NZ705848A (en) | Anti-cd38 antibodies | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2012154339A (ru) | НОВОЕ АНТИТЕЛО ПРОТИВ c-Met | |
| JP2014503189A5 (OSRAM) | ||
| JP2020536109A5 (OSRAM) | ||
| JP2020502271A5 (OSRAM) | ||
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2018534933A5 (OSRAM) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2016531915A5 (OSRAM) | ||
| JP2010526028A5 (OSRAM) | ||
| JP2010531140A5 (OSRAM) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |